N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=256 Analysis of BPD in Premature Infants With Typical Imaging Changes
Bronchopulmonary Dysplasia
Primary: Mortality — 17; 7 Participants
Phase 2 N=124 Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Bronchopulmonary Dysplasia
Primary: Combined Endpoint of Bronchopulmonary Dysplasia (BPD) or Mortality — 1; 2; 24; 25 Participants
N/A N=50 BPD Saturation TARgeting
Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Chronic Lung Disease
Primary: Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time — 2.2; 1.2 IH events per 8 hours of monitoring time
Phase 2 N=125 Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia of Newborn
Primary: Safety Based Upon Number of Participants With Hypotension — 1; 0; 0; 0 Participants
N/A N=187 GER Poses a Potential Risk for Late Complications of BPD
Gastroesophageal Reflux · Bronchopulmonary Dysplasia
Primary: the Late Complications of BPD Infants — 57; 45; 30; 4 Participants
Phase 4 N=14 Preterm Infant Inhaled Albuterol Dosing
Bronchopulmonary Dysplasia · Very Low Birth Weight
Primary: Change in Respiratory Resistance — 0.011; 0.006; 0.014 cm h2o/mL/sec
N/A N=24 Aerosolized Albuterol Use in Severe BPD
Severe Bronchopulmonary Dysplasia
Primary: Change in Expiratory Flow Between Pre and Post-medication Dosing — 0.38; 0.70; 0.45 L/min
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
Phase 1 N=16 Inhaled Tobramycin in BPD
Bronchopulmonary Dysplasia
Primary: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event — 0; 0; 0; 1 Participants
Phase 3 N=511 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia
Primary: Survival Without BPD at 36 Weeks Post Menstrual Age. — 79; 82 Participants — p=0.89
Phase 2 N=82 Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Events — 123; 29; 100; 49 Events
Phase 3 N=451 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Bronchopulmonary Dysplasia
Primary: Survival Without BPD at 36 Weeks — 80; 70; 149; 152 participants — p=0.427
Phase 3 N=85 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction) · Bronchopulmonary Dysplasia
Primary: SP-B Content — 19.9; 13.3 Total surfactant protein (% of PL)
N/A N=1,493 A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants Following Extubation
Intubated Infants Were Intend to Extubation Using Noninvasive Ventilation Strategies
Primary: Duration of Invasive Mechanical Ventilation — 6.3; 7.8; 7.3 day
Phase 3 N=800 Hydrocortisone for BPD
Infant, Newborn · Infant, Small for Gestational Age · Infant, Very Low Birth Weight
Primary: Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD) — 332; 349; 66; 53 Participants
Phase 2 N=220 Trial II of Lung Protection With Azithromycin in the Preterm Infant
Bronchopulmonary Dysplasia
Primary: Incidence of Bronchopulmonary Dysplasia (BPD) — 76; 84 percentage w/ BPD — p=0.20
Phase 2 N=149 Aerosolized Surfactant in Neonatal RDS
Respiratory Distress Syndrome, Newborn
Primary: Number of Participants With Adverse Events as a Measure of Safety and Feasibility — 3; 8; 4; 12 Participants
Phase 3 N=648 Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Primary: Death or Chronic Lung Disease — 76; 68; 62 participants
Phase 2 N=106 Safety of Sildenafil in Premature Infants
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Event Experienced by Participants — 71; 83; 53; 60 Events
Phase 2 N=123 A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Respiratory Distress Syndrome, Newborn
Primary: Oxygen Requirement and Ventilatory Support -- SpO2/FiO2 Ratio — 3.33; 3.31; 3.36; 3.55 SpO2/FiO2 ratio — p=0.930
N/A N=100 Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function
Neonatal · Premature Birth · Respiratory Distress Syndrome
Primary: Alveolar Volume — 500.2; 418.1 mL — p=<0.05
Phase 4 N=11 Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
Pulmonary Infections
Primary: Percent Reduction in Oxygen Requirement From Baseline — 5.4; 16.5 percentage FiO2
N/A N=39 ABCA3 Gene and RDS in Late Preterm and Term Infants
Respiratory Distress Syndrome, Newborn
Primary: Mortality — 5; 3; 5 Participants
N/A N=995 Neonatal Outcome by Reason for Delivery
Preterm Delivery
Primary: Composite Perinatal Morbidity — 277; 203; 221; 45 participants
N/A N=50 Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
Respiratory Distress Syndrome · Bronchopulmonary Dysplasia
Primary: Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants — 12.6; 6.4; 27.2; 17.1 mL — p=<0.05
Phase 3 N=800 Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies
Lung Disease
Primary: Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress — 258; 262 Participants — p=0.7340
N/A N=21 Delayed Cord Clamping for Congenital Diaphragmatic Hernia
Congenital Diaphragmatic Hernia
Primary: Proportion of Infants Who Are Intubated Prior to Umbilical Cord Clamping — 17 Participants
Phase 3 N=1,316 Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Infant, Newborn, Diseases · Other Preterm Infants · Infant, Small for Gestational Age
Primary: Survival Without Bronchopulmonary Dysplasia (BPD) — 346; 320 Participants
N/A N=200 Trial of Non Invasive Ventilation for Respiratoy Distress Syndrome
Prematurity · Respiratory Distress Syndrome
Primary: Need for Endotracheal Ventilation in the First 72 hs of Life — 34; 25 participants — p=<0.05